A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs TAS 205 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 05 Feb 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 26 Dec 2016 Status changed from recruiting to active, no longer recruiting.